HBV-TAG Conférence 2021 (Sponsorship)

Publié le 18/05/2021

11-12 Juin 2021
Conférence virtuelle

ENYO Pharma a sponsorisé la conférence inaugurale virtuelle sur l’hépatite B – agents thérapeutiques de 2021.
www.hbv-tag.org
“The primary objective of the Virtual HBV-TAG Conference is to meet the educational needs of research and development stakeholders and healthcare professionals who seek to improve the lives of patients with HBV. The aim of the HBV-TAG conference is to bring together key opinion leaders from the teams of clinicians that care for patients with HBV (hepatologists and gastroenterologists) and pharmaceutical industry representatives to discuss optimized trial design, patient populations, therapeutic endpoints, as well as the potential benefits these agents can have for patients with HBV. This conference will deliver a focused scientific educational update that highlights the most clinically relevant advances in HBV to guide future directions in diagnostic procedures and the development of therapeutic agents for HBV.”

Notre stand d’exposition virtuelle nous a permis de présenter des résultats préliminaires de notre composé phare Vonafexor (EYP001, FXR agonist) dans une étude de Phase 2a traitant des patients naïfs souffrant d’une hépatite B chronique :

À lire dans 'Événements'

• J.P. Morgan week et WuXi Global Forum 2025 à San Francisco
• 4th Rare & Genetic Kidney Disease Drug Development Summit
• MOSAIC - Global NASH Trialist Forum 2024
• The 2024 international workshop on Alport syndrome
• Alport Connect 2024, la rencontre annuelle américaine avec les patients atteints du syndrome d’Alport